|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.10.25 - 14:03
|
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrologys Kidney Week (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations supporting XPHOZAH® (tenapanor) at the American Society of Nephrology's Kidney Week, to be held November 5-9, 2025, in Houston....
|
|
|
|
|
|
|
13.10.25 - 14:33
|
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.08.25 - 14:03
|
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
|
|
|
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors.
Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.
Mr. Solari brings over 30 years of legal and financial experience in corporate gov...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
